RS58709B1 - Miševi koji čine antitela teškog lanca - Google Patents

Miševi koji čine antitela teškog lanca

Info

Publication number
RS58709B1
RS58709B1 RS20190538A RSP20190538A RS58709B1 RS 58709 B1 RS58709 B1 RS 58709B1 RS 20190538 A RS20190538 A RS 20190538A RS P20190538 A RSP20190538 A RS P20190538A RS 58709 B1 RS58709 B1 RS 58709B1
Authority
RS
Serbia
Prior art keywords
mouse
gene
human
light chain
locus
Prior art date
Application number
RS20190538A
Other languages
English (en)
Serbian (sr)
Inventor
Lynn Macdonald
Sean Stevens
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of RS58709B1 publication Critical patent/RS58709B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RS20190538A 2009-12-10 2010-12-10 Miševi koji čine antitela teškog lanca RS58709B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28525009P 2009-12-10 2009-12-10
EP15177538.4A EP2954779B1 (en) 2009-12-10 2010-12-10 Mice that make heavy chain antibodies

Publications (1)

Publication Number Publication Date
RS58709B1 true RS58709B1 (sr) 2019-06-28

Family

ID=43534479

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20190538A RS58709B1 (sr) 2009-12-10 2010-12-10 Miševi koji čine antitela teškog lanca

Country Status (24)

Country Link
US (9) US8754287B2 (cg-RX-API-DMAC7.html)
EP (3) EP2954779B1 (cg-RX-API-DMAC7.html)
JP (5) JP5909449B2 (cg-RX-API-DMAC7.html)
KR (2) KR101553244B1 (cg-RX-API-DMAC7.html)
CN (3) CN104131035A (cg-RX-API-DMAC7.html)
AU (1) AU2010328046C1 (cg-RX-API-DMAC7.html)
CA (1) CA2782936C (cg-RX-API-DMAC7.html)
CY (2) CY1118163T1 (cg-RX-API-DMAC7.html)
DK (2) DK2509409T3 (cg-RX-API-DMAC7.html)
ES (2) ES2595376T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20190820T1 (cg-RX-API-DMAC7.html)
HU (2) HUE043556T2 (cg-RX-API-DMAC7.html)
IL (4) IL220150A0 (cg-RX-API-DMAC7.html)
LT (2) LT2954779T (cg-RX-API-DMAC7.html)
MY (2) MY172472A (cg-RX-API-DMAC7.html)
PL (2) PL2509409T3 (cg-RX-API-DMAC7.html)
PT (2) PT2954779T (cg-RX-API-DMAC7.html)
RS (1) RS58709B1 (cg-RX-API-DMAC7.html)
RU (1) RU2603102C2 (cg-RX-API-DMAC7.html)
SG (2) SG181477A1 (cg-RX-API-DMAC7.html)
SI (2) SI2509409T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900251T1 (cg-RX-API-DMAC7.html)
TR (1) TR201906488T4 (cg-RX-API-DMAC7.html)
WO (1) WO2011072204A1 (cg-RX-API-DMAC7.html)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2440990T5 (es) 2004-07-22 2022-10-25 Univ Erasmus Med Ct Rotterdam Moléculas de unión
DK2346994T3 (da) 2008-09-30 2022-02-28 Ablexis Llc Knock-in-mus til fremstilling af kimære antistoffer
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
EP2517556B2 (en) 2009-07-08 2023-03-22 Kymab Limited Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
DK2509409T3 (en) * 2009-12-10 2016-11-14 Regeneron Pharma MICE, WHICH PRODUCES HEAVY CHAIN ANTIBODIES
WO2011097603A1 (en) 2010-02-08 2011-08-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
KR102004106B1 (ko) 2010-03-31 2019-07-25 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
DK2597945T3 (da) 2010-07-26 2020-09-21 Trianni Inc Transgene dyr og fremgangsmåder til anvendelse deraf
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
RS55495B1 (sr) 2010-08-02 2017-04-28 Regeneron Pharma Miševi koji stvaraju vezujuće proteine koji sadrže vl domene
HRP20230526T1 (hr) 2011-02-25 2023-09-01 Regeneron Pharmaceuticals, Inc. Adam6 miševi
CA2828347A1 (en) * 2011-03-10 2012-09-13 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
SI3865581T1 (sl) 2011-08-05 2024-12-31 Regeneron Pharmaceuticals, Inc. Miši s humanizirano univerzalno lahko verigo
GB2501753A (en) * 2012-05-04 2013-11-06 Kymab Ltd Human antibodies
CA2846319A1 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
EP2761008A1 (en) * 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
SG10202010120XA (en) 2011-10-17 2020-11-27 Regeneron Pharma Restricted immunoglobulin heavy chain mice
WO2013082463A2 (en) * 2011-11-30 2013-06-06 Wellstat Diagnostics, Llc. Assays, antibodies, immunogens and compositions related to 5-fu
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
PL2793567T3 (pl) 2011-12-20 2019-09-30 Regeneron Pharmaceuticals, Inc. Myszy z humanizowanym łańcuchem lekkim
HUE045537T2 (hu) 2012-03-16 2019-12-30 Regeneron Pharma PH-érzékeny immunglobulin-szekvenciákat expresszáló rágcsálók
AU2013204581B2 (en) 2012-03-16 2015-06-25 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
RU2644684C2 (ru) 2012-03-16 2018-02-13 Регенерон Фармасьютикалз, Инк. Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
JP2015512635A (ja) 2012-03-28 2015-04-30 カイマブ・リミテッド クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
CN104540383B (zh) 2012-06-12 2017-08-29 瑞泽恩制药公司 具有受限制的免疫球蛋白重链基因座的人源化非人动物
WO2014130690A1 (en) * 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
EP2958937B1 (en) * 2013-02-22 2018-08-15 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
ES2839087T3 (es) * 2013-11-12 2021-07-05 Ogd2 Pharma Anticuerpo derivado de IGG1 humana con actividad pro-apoptótica
ES2872475T3 (es) * 2014-03-21 2021-11-02 Regeneron Pharma Animales no humanos que producen proteínas de unión de dominio único
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
ES2794942T3 (es) * 2014-04-08 2020-11-19 Regeneron Pharma Animales no humanos que tienen receptores Fc-gamma humanizados
MY181896A (en) 2014-06-06 2021-01-12 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
CN104177496B (zh) * 2014-09-02 2015-03-11 安源生物科技(上海)有限公司 人IgG2抗体铰链区修饰体
JP2017531642A (ja) 2014-10-03 2017-10-26 マサチューセッツ インスティテュート オブ テクノロジー エボラ糖タンパク質に結合する抗体およびその使用
AU2014409276A1 (en) * 2014-10-22 2017-04-06 Crescendo Biologics Limited Transgenic mice
US10100129B2 (en) 2014-11-21 2018-10-16 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
PL3233912T3 (pl) 2014-12-19 2021-12-27 Regenesance B.V. Przeciwciała, które wiążą ludzkie c6 oraz ich zastosowania
EP3237448A1 (en) 2014-12-23 2017-11-01 Bristol-Myers Squibb Company Antibodies to tigit
JP2018508224A (ja) 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
HUE061253T2 (hu) 2015-05-29 2023-06-28 Bristol Myers Squibb Co Antitestek OX40 ellen és azok felhasználásai
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017035252A1 (en) * 2015-08-24 2017-03-02 Trianni, Inc. Enhanced production of immunoglobulins
CN105441455B (zh) * 2015-10-21 2020-08-28 重庆金迈博生物科技有限公司 一种嵌合核酸分子及其在人源化抗体制备中的应用
JP6983776B2 (ja) 2015-11-19 2021-12-17 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company グルココルチコイド誘発腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
US11053288B2 (en) 2016-02-04 2021-07-06 Trianni, Inc. Enhanced production of immunoglobulins
KR20220033522A (ko) 2016-03-04 2022-03-16 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
EP4406550A3 (en) 2016-03-04 2024-10-16 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
TW201805309A (zh) * 2016-04-21 2018-02-16 艾伯維史坦森特瑞斯有限責任公司 新穎抗－bmpr1b抗體及使用方法
EP3455256A1 (en) 2016-05-09 2019-03-20 Bristol-Myers Squibb Company Tl1a antibodies and uses thereof
AU2017268458B2 (en) 2016-05-20 2022-07-21 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide RNAS
EP3462853B1 (en) * 2016-06-03 2023-03-01 Regeneron Pharmaceuticals, Inc. Rodents expressing exogenous terminal deoxynucleotidyltransferase
EP4512829A3 (en) 2016-07-14 2025-06-11 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CR20210094A (es) 2016-10-13 2021-03-31 Massachusetts Inst Technology ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ENVOLTURA DEL VIRUS ZIKA Y USOS DE LOS MISMOS (Divisional 2019-0193)
CN109906030B (zh) * 2016-11-04 2022-03-18 安健基因公司 用于产生仅重链抗体的经基因修饰的非人动物和方法
KR102573778B1 (ko) 2017-02-17 2023-08-31 브리스톨-마이어스 스큅 컴퍼니 알파-시뉴클레인에 대한 항체 및 그의 용도
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
AU2018290882B2 (en) 2017-06-27 2023-07-27 Regeneron Pharmaceuticals, Inc. Tropism-modified recombinant viral vectors and uses thereof for the targeted introduction of genetic material into human cells
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
EP4219529A1 (en) 2017-06-27 2023-08-02 Regeneron Pharmaceuticals, Inc. Tropism-modified recombinant viral particles and uses thereof for the targeted introduction of genetic material into human cells
JP6677277B2 (ja) 2017-07-19 2020-04-08 株式会社デンソー 車両用制御装置及び電源供給回路
IL271818B2 (en) 2017-07-21 2024-10-01 Trianni Inc Single chain vh and heavy chain antibodies
AU2018396970B2 (en) 2017-12-28 2025-09-25 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against TIGIT
AU2018396964C1 (en) 2017-12-28 2024-10-03 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against PD-L1
CN120192415A (zh) 2018-01-12 2025-06-24 百时美施贵宝公司 抗tim3抗体及其用途
CN111699200B (zh) 2018-01-15 2023-05-26 南京传奇生物科技有限公司 针对pd-1的单域抗体和其变体
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
HUE070158T2 (hu) 2018-03-24 2025-05-28 Regeneron Pharma Genetikailag módosított egerek vagy patkányok peptid-mhc komplexek elleni terápiás antitestek létrehozásra, ezek elõállítására szolgáló módszerek, valamint alkalmazásuk
AU2019242586B2 (en) * 2018-03-26 2025-09-11 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
US11958903B2 (en) 2018-03-30 2024-04-16 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
JP2021525806A (ja) 2018-06-01 2021-09-27 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 疾患または状態を処置するための組成物およびそれらの使用
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
JP7515410B2 (ja) * 2018-06-13 2024-07-12 クリスタル バイオサイエンス インコーポレイテッド 複数のジスルフィド架橋によって安定化され、遺伝子変換によって多様化された長いｃｄｒ－ｈ３ｓで抗体を作製するトランスジェニックニワトリ
US12102070B2 (en) * 2018-06-13 2024-10-01 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
US20210227810A1 (en) * 2018-06-13 2021-07-29 Crystal Bioscience Inc. Production of antibodies by modification of an autonomous heavy chain variable domain by gene conversion
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
US12275788B2 (en) 2018-09-10 2025-04-15 Legend Biotech Ireland Limited Single-domain antibodies against CD33 and constructs thereof
SG11202104969RA (en) 2018-11-16 2021-06-29 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
KR20230128134A (ko) 2019-01-22 2023-09-01 브리스톨-마이어스 스큅 컴퍼니 Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
US12263234B2 (en) 2019-01-23 2025-04-01 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-PD-L1 diabodies and the use thereof
JP2022533438A (ja) 2019-05-24 2022-07-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改変ウイルス粒子およびその使用
EP4069722A1 (en) 2019-12-02 2022-10-12 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
BR112022016491A2 (pt) 2020-02-28 2022-10-11 Shanghai Henlius Biotech Inc Construto anti-cd137 e usos do mesmo
KR20220145859A (ko) 2020-02-28 2022-10-31 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물, 다중 특이적 항체 및 그 용도
CN111333719B (zh) * 2020-03-16 2021-10-01 西南大学 抗hpv16e7蛋白单抗69a6、杂交瘤细胞及其制备方法和应用
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
US20230235075A1 (en) 2020-06-02 2023-07-27 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
WO2021257679A1 (en) 2020-06-17 2021-12-23 Janssen Biotech, Inc. Materials and methods for the manufacture of pluripotent stem cells
US20230235048A1 (en) 2020-06-24 2023-07-27 Andriani IOANNOU Antibodies recognizing sortilin
WO2022011457A1 (en) * 2020-07-13 2022-01-20 Kisoji Biotechnology Inc. Transgenic animals expressing heavy chain antibodies
AU2021315665A1 (en) 2020-07-29 2023-03-16 Dynamicure Biotechnology Llc Anti-CD93 constructs and uses thereof
KR20230062833A (ko) 2020-08-10 2023-05-09 얀센 바이오테크 인코포레이티드 생물공학적 바이러스 특이적 림프구 생산을 위한 재료 및 방법
CN114134144A (zh) * 2020-09-04 2022-03-04 北京仁源欣生生物科技有限公司 一种非人哺乳动物或其子代的制备方法及其应用
IL301137A (en) 2020-09-11 2023-05-01 Regeneron Pharma Identification and production of antigen-specific antibodies
CN118126189A (zh) 2020-09-28 2024-06-04 安济盛生物医药有限公司 抗硬骨抑素构建体及其用途
US20240023526A1 (en) 2020-12-09 2024-01-25 Trianni, Inc. Heavy chain-only antibodies
CN116848254A (zh) 2020-12-16 2023-10-03 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
EP4559939A3 (en) 2020-12-23 2025-09-24 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses therof
EP4296282A4 (en) 2021-02-19 2025-02-26 SHAPERON Inc. SINGLE DOMAIN ANTIBODIES AGAINST CD47 AND USE THEREOF
KR102836733B1 (ko) 2021-02-19 2025-07-21 (주)샤페론 Pd-l1 및 cd47에 대한 이중특이적 단일 도메인 항체 및 이의 용도
WO2022177393A1 (ko) 2021-02-19 2022-08-25 (주)샤페론 Pd-l1에 대한 단일 도메인 항체 및 이의 용도
EP4301472A1 (en) 2021-03-05 2024-01-10 Dynamicure Biotechnology LLC Anti-vista constructs and uses thereof
JP2024511424A (ja) 2021-03-25 2024-03-13 ダイナミキュア バイオテクノロジー エルエルシー 抗ｉｇｆｂｐ７構築物およびその使用
JP7555296B2 (ja) * 2021-03-31 2024-09-24 太平洋セメント株式会社 二酸化炭素の固定化方法
AU2022271276A1 (en) * 2021-05-05 2023-11-09 Leveragen, Inc. Engineered non-human animals for producing antibodies
CN117651486A (zh) * 2021-05-05 2024-03-05 利威瑞健股份有限公司 用于生产抗体的工程改造的非人动物
EP4342908A4 (en) * 2021-06-17 2024-10-23 Fapon Biotech Inc. CHIMERIC IMMUNGLOBULIN
EP4355785A1 (en) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
WO2022269473A1 (en) 2021-06-23 2022-12-29 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
US20250304918A1 (en) 2021-11-04 2025-10-02 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to skeletal muscle
CA3240565A1 (en) 2021-12-17 2023-06-22 Wenfeng Xu Anti-ox40 antibodies and methods of use
CN118488965A (zh) 2021-12-17 2024-08-13 上海复宏汉霖生物技术股份有限公司 抗ox40抗体、多特异性抗体及其使用方法
EP4482861A2 (en) * 2022-02-24 2025-01-01 A & G Pharmaceutical, Inc. Fully human monoclonal antibodies against human progranulin
AU2023240941A1 (en) 2022-03-25 2024-09-19 Shanghai Henlius Biologics Co., Ltd. Anti-msln antibodies and methods of use
JP2025516527A (ja) 2022-05-09 2025-05-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド インビボ抗体産生のためのベクター及び方法
WO2024018426A1 (en) 2022-07-22 2024-01-25 Janssen Biotech, Inc. Enhanced transfer of genetic instructions to effector immune cells
JP2025525792A (ja) 2022-07-29 2025-08-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド トランスフェリン受容体１に対して再標的化されるウイルス粒子
EP4584296A1 (en) 2022-09-07 2025-07-16 Dynamicure Biotechnology LLC Anti-vista constructs and uses thereof
WO2024056044A1 (en) * 2022-09-16 2024-03-21 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals and methods for producing heavy-chain antibodies
WO2024102454A1 (en) * 2022-11-09 2024-05-16 Leveragen, Inc. Engineered non-human animals
EP4658687A1 (en) 2023-01-31 2025-12-10 University of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024229105A1 (en) 2023-05-02 2024-11-07 Regeneron Pharmaceuticals, Inc. Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
EP4512243A1 (en) 2023-08-21 2025-02-26 Kymab Limited Binding molecules
WO2025045250A1 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Anti-human factor d antibody constructs and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025151796A1 (en) 2024-01-11 2025-07-17 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to nervous system tissues
WO2025178959A1 (en) 2024-02-20 2025-08-28 University Of Georgia Research Foundation, Inc. Single-domain antibodies and variants thereof against tab1
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
AU781922B2 (en) * 1991-12-17 2005-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
PT1589107E (pt) 1992-08-21 2010-03-29 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
US6080910A (en) 1997-02-20 2000-06-27 Case Western Reserve University Transgenic knockout animals lacking IgG3
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
EP1311530A4 (en) 2000-08-03 2004-10-06 Wim-Van Schooten PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7235643B2 (en) 2000-11-07 2007-06-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with high affinity
CN101016543A (zh) * 2000-11-17 2007-08-15 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
GB0110029D0 (en) * 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
EP2135879A3 (en) 2002-06-28 2010-06-23 Domantis Limited Ligand
US7241733B2 (en) 2002-06-28 2007-07-10 Centocor, Inc. Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
FR2861255B1 (fr) * 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
US7534604B2 (en) 2004-01-16 2009-05-19 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
US20060024302A1 (en) * 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
ES2440990T5 (es) * 2004-07-22 2022-10-25 Univ Erasmus Med Ct Rotterdam Moléculas de unión
PL1802193T3 (pl) 2004-10-19 2014-09-30 Regeneron Pharma Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
WO2006117699A2 (en) 2005-04-29 2006-11-09 Innate Pharma Transgenic animals and methods of making recombinant antibodies
EP1973576B1 (en) 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
GB0618345D0 (en) * 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
JP5184374B2 (ja) 2006-01-25 2013-04-17 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 対立遺伝子排除
EP2322931A3 (en) * 2006-03-22 2011-08-31 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
CN101454345B (zh) 2006-06-02 2012-08-08 瑞泽恩制药公司 人il-6受体的高亲和力抗体
GB0706628D0 (en) 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
SI2602323T1 (en) 2007-06-01 2018-05-31 Open Monoclonal Technology, Inc. Compositions and procedures for inhibiting endogenous immunoglobin gene and the formation of transgenic human idiopathic antibodies
MX2009013393A (es) 2007-06-08 2010-02-09 Dow Global Technologies Inc Expresion de fragmento de anticuerpo soluble mediante truncamiento de dominio de ch1.
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
KR20100087283A (ko) 2007-09-07 2010-08-04 심포젠 에이/에스 항­ｒｓｖ 항체의 재조합 제조 방법
EP2262898B1 (en) 2008-03-07 2018-01-24 Regeneron Pharmaceuticals, Inc. Es cell-derived mice from diploid host embryo injection
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
DK2509409T3 (en) * 2009-12-10 2016-11-14 Regeneron Pharma MICE, WHICH PRODUCES HEAVY CHAIN ANTIBODIES
JP6023667B2 (ja) * 2013-06-26 2016-11-09 矢崎総業株式会社 コネクタ
JP5602929B1 (ja) * 2013-11-08 2014-10-08 株式会社小松製作所 モータグレーダのリッパー装置およびこれを備えたモータグレーダ

Also Published As

Publication number Publication date
US11234419B2 (en) 2022-02-01
US8754287B2 (en) 2014-06-17
IL257822A (en) 2018-04-30
RU2012128856A (ru) 2014-01-20
US20150197556A1 (en) 2015-07-16
AU2010328046C1 (en) 2018-01-18
IL237818A (en) 2016-08-31
JP2015077147A (ja) 2015-04-23
JP6271450B2 (ja) 2018-01-31
SG10201408181PA (en) 2015-01-29
IL237819A (en) 2017-03-30
US20110145937A1 (en) 2011-06-16
WO2011072204A1 (en) 2011-06-16
EP2509409B1 (en) 2016-07-27
MY173363A (en) 2020-01-21
LT2954779T (lt) 2019-05-27
LT2509409T (lt) 2016-12-12
JP6293702B2 (ja) 2018-03-14
JP5909449B2 (ja) 2016-04-26
HRP20190820T1 (hr) 2019-09-20
CN102711449A (zh) 2012-10-03
HUE030208T2 (en) 2017-04-28
SI2954779T1 (sl) 2019-06-28
US20140289876A1 (en) 2014-09-25
CY1121608T1 (el) 2020-05-29
US20220201993A1 (en) 2022-06-30
CA2782936C (en) 2019-06-18
IL257822B (en) 2020-01-30
RU2603102C2 (ru) 2016-11-20
HK1177100A1 (en) 2013-08-16
JP2019141095A (ja) 2019-08-29
AU2010328046B2 (en) 2014-07-31
JP6615830B2 (ja) 2019-12-04
PT2509409T (pt) 2016-09-29
SMT201900251T1 (it) 2019-07-11
EP2509409A1 (en) 2012-10-17
JP2017140058A (ja) 2017-08-17
US20150197553A1 (en) 2015-07-16
JP2013513388A (ja) 2013-04-22
CN102711449B (zh) 2015-01-07
SG181477A1 (en) 2012-07-30
US9888675B2 (en) 2018-02-13
MY172472A (en) 2019-11-26
IL220150A0 (en) 2012-07-31
HK1220865A1 (en) 2017-05-19
DK2509409T3 (en) 2016-11-14
KR101430514B1 (ko) 2014-08-19
US20150197554A1 (en) 2015-07-16
EP2954779A1 (en) 2015-12-16
US20150197557A1 (en) 2015-07-16
KR20130055556A (ko) 2013-05-28
US20150196015A1 (en) 2015-07-16
US20150197555A1 (en) 2015-07-16
KR101553244B1 (ko) 2015-09-15
PT2954779T (pt) 2019-05-29
AU2010328046A1 (en) 2012-07-12
CN110079550A (zh) 2019-08-02
PL2509409T3 (pl) 2017-02-28
CN104131035A (zh) 2014-11-05
TR201906488T4 (tr) 2019-05-21
DK2954779T3 (da) 2019-05-13
CY1118163T1 (el) 2017-06-28
EP3504964A1 (en) 2019-07-03
CA2782936A1 (en) 2011-06-16
ES2595376T3 (es) 2016-12-29
KR20140024970A (ko) 2014-03-03
EP2954779B1 (en) 2019-02-06
PL2954779T3 (pl) 2019-07-31
HUE043556T2 (hu) 2019-09-30
JP2015133991A (ja) 2015-07-27
ES2724975T3 (es) 2019-09-18
SI2509409T1 (sl) 2016-12-30

Similar Documents

Publication Publication Date Title
JP7236409B2 (ja) ヒトλ可変領域およびマウス定常領域を含む軽鎖を発現するマウス
RS58709B1 (sr) Miševi koji čine antitela teškog lanca
HK1242732A1 (en) Mice with humanised lambda variable gene segments